D.E. Shaw & Co’s MoonLake Immunotherapeutics MLTX Stock Holding History

D.E. Shaw & Co’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.6M	Sell	2,390,661 -90,106	-4%	-$1.49M	0.03%	710
2025 Q4	$32.7M	Buy	+2,480,767	New	+$29.3M	0.02%	943
2024 Q1	–	Sell	-128,700	Closed	-$7.77M	–	4586
2023 Q4	$7.77M	Buy	+128,700	New	+$6.63M	0.01%	1569
2022 Q2	–	Sell	-337,021	Closed	-$3.74M	–	5595
2022 Q1	$3.74M	Hold	337,021	–	–	﹤0.01%	2656
2021 Q4	$3.33M	Buy	337,021 +296,968	+741%	+$2.95M	﹤0.01%	2831
2021 Q3	$395K	Buy	40,053 +17,040	+74%	+$170K	﹤0.01%	4219
2021 Q2	$238K	Buy	+23,013	New	+$234K	﹤0.01%	4391

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co's MLTX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its MoonLake Immunotherapeutics (MLTX) stake by 3.6% in Q1 2026, selling an estimated $1.49M and leaving 2,390,661 shares worth $44.6M. The position accounts for 0.03% of the portfolio, ranked #710.

D.E. Shaw & Co first reported a position in MLTX in Q2 2021 and has held it in 7 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

D.E. Shaw & Co held 2,390,661 shares of MoonLake Immunotherapeutics worth $44.6M as of Q1 2026.
D.E. Shaw & Co sold 90,106 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $1.49M.
MoonLake Immunotherapeutics made up 0.03% of D.E. Shaw & Co's portfolio in Q1 2026, its #710 holding.
D.E. Shaw & Co first reported a position in MoonLake Immunotherapeutics in Q2 2021 and has held it in 7 quarters since.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.